,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-12-16 07:00:00,The following are the top rated Healthcare stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch .,0.051244959235191345,0.004840875510126352,0.9439141750335693,neutral,0.04640408232808113
1,2018-12-16 07:00:00,This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.,0.44832858443260193,0.01002567633986473,0.5416457653045654,neutral,0.4383029043674469
2,2018-12-16 07:00:00,UNITED THERAPEUTICS CORPORATION ( UTHR ) is a mid-cap value stock in the Biotechnology & Drugs industry.,0.12496162950992584,0.006567221600562334,0.8684711456298828,neutral,0.1183944046497345
3,2018-12-16 07:00:00,The rating according to our strategy based on Peter Lynch is 93% based on the firm's underlying fundamentals and the stock's valuation.,0.03087104670703411,0.005318591371178627,0.9638103246688843,neutral,0.025552455335855484
4,2018-12-16 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
5,2018-12-16 07:00:00,Company Description: United Therapeutics Corporation is a biotechnology company.,0.014488255605101585,0.008135340176522732,0.9773764610290527,neutral,0.006352915428578854
6,2018-12-16 07:00:00,The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions.,0.061649151146411896,0.0042084017768502235,0.9341424107551575,neutral,0.05744075030088425
7,2018-12-16 07:00:00,The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension ( PAH ): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).,0.03540993854403496,0.00542250694707036,0.9591675400733948,neutral,0.029987432062625885
8,2018-12-16 07:00:00,"The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma.",0.08270557224750519,0.005279029253870249,0.9120153784751892,neutral,0.07742654532194138
9,2018-12-16 07:00:00,The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.,0.10041551291942596,0.0044503179378807545,0.8951341509819031,neutral,0.0959651917219162
10,2018-12-16 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
11,2018-12-16 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
12,2018-12-16 07:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BAXTER INTERNATIONAL INC ( BAX ) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.5010000467300415,0.009393168613314629,0.48960670828819275,positive,0.4916068911552429
13,2018-12-16 07:00:00,The rating according to our strategy based on Peter Lynch is 91% based on the firm's underlying fundamentals and the stock's valuation.,0.029384789988398552,0.005245543550699949,0.965369701385498,neutral,0.024139245972037315
14,2018-12-16 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
15,2018-12-16 07:00:00,"Company Description: Baxter International Inc., through its subsidiaries, provides renal and hospital products.",0.016776859760284424,0.00666993809863925,0.9765532612800598,neutral,0.010106921195983887
16,2018-12-16 07:00:00,The Company operates through two segments: Hospital Products and Renal.,0.015520949847996235,0.00666307145729661,0.9778159856796265,neutral,0.008857877925038338
17,2018-12-16 07:00:00,"Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.",0.023244887590408325,0.005879237316548824,0.9708758592605591,neutral,0.017365649342536926
18,2018-12-16 07:00:00,"The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis ( HD ), continuous renal replacement therapy (CRRT) and additional dialysis services.",0.13980115950107574,0.004776298999786377,0.8554225564002991,neutral,0.13502486050128937
19,2018-12-16 07:00:00,"Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.",0.01395258679986,0.007541074883192778,0.9785063862800598,neutral,0.006411511916667223
20,2018-12-16 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
21,2018-12-16 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
22,2018-12-16 07:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BIOGEN INC ( BIIB ) is a large-cap value stock in the Biotechnology & Drugs industry.",0.06658420711755753,0.005604018457233906,0.9278118014335632,neutral,0.060980189591646194
23,2018-12-16 07:00:00,The rating according to our strategy based on Peter Lynch is 91% based on the firm's underlying fundamentals and the stock's valuation.,0.029384789988398552,0.005245543550699949,0.965369701385498,neutral,0.024139245972037315
24,2018-12-16 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
25,2018-12-16 07:00:00,Company Description: Biogen Inc. is a biopharmaceutical company.,0.015894627198576927,0.0073434701189398766,0.9767618775367737,neutral,0.00855115707963705
26,2018-12-16 07:00:00,"The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.",0.06928692013025284,0.00443440955132246,0.9262787103652954,neutral,0.0648525133728981
27,2018-12-16 07:00:00,"The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).",0.05885586515069008,0.004554904066026211,0.9365891814231873,neutral,0.05430096015334129
28,2018-12-16 07:00:00,"It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies.",0.4847475290298462,0.009223067201673985,0.5060294270515442,neutral,0.4755244553089142
29,2018-12-16 07:00:00,"The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.",0.05369625240564346,0.005773114040493965,0.9405306577682495,neutral,0.04792314022779465
30,2018-12-16 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
31,2018-12-16 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
32,2018-12-16 07:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BRISTOL-MYERS SQUIBB CO (BMY) is a large-cap growth stock in the Biotechnology & Drugs industry.",0.3397698998451233,0.007557128556072712,0.6526729464530945,neutral,0.33221277594566345
33,2018-12-16 07:00:00,The rating according to our strategy based on Peter Lynch is 91% based on the firm's underlying fundamentals and the stock's valuation.,0.029384789988398552,0.005245543550699949,0.965369701385498,neutral,0.024139245972037315
34,2018-12-16 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
35,2018-12-16 07:00:00,"Company Description: Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products.",0.01906360127031803,0.0065475632436573505,0.974388837814331,neutral,0.012516038492321968
36,2018-12-16 07:00:00,"The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.",0.01180163212120533,0.007980850525200367,0.980217456817627,neutral,0.003820781596004963
37,2018-12-16 07:00:00,Small molecule drugs are administered orally in the form of a pill or tablet.,0.020318880677223206,0.01081310585141182,0.9688679575920105,neutral,0.009505774825811386
38,2018-12-16 07:00:00,Biologics are administered to patients through injections or by infusion.,0.02115056850016117,0.009453384205698967,0.9693961143493652,neutral,0.011697184294462204
39,2018-12-16 07:00:00,"The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise.",0.036300886422395706,0.0045506893657147884,0.9591484665870667,neutral,0.03175019845366478
40,2018-12-16 07:00:00,"It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular.",0.029038988053798676,0.004604616668075323,0.9663563370704651,neutral,0.024434370920062065
41,2018-12-16 07:00:00,"Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.",0.031688861548900604,0.004590547177940607,0.9637206196784973,neutral,0.027098314836621284
42,2018-12-16 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
43,2018-12-16 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
44,2018-12-16 07:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

CAMBREX CORPORATION (CBM) is a small-cap value stock in the Biotechnology & Drugs industry.",0.02062930539250374,0.008442523889243603,0.9709281921386719,neutral,0.012186781503260136
45,2018-12-16 07:00:00,The rating according to our strategy based on Peter Lynch is 91% based on the firm's underlying fundamentals and the stock's valuation.,0.029384789988398552,0.005245543550699949,0.965369701385498,neutral,0.024139245972037315
46,2018-12-16 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
47,2018-12-16 07:00:00,Company Description: Cambrex Corporation (Cambrex) is a life sciences company.,0.02071075327694416,0.005717118736356497,0.9735721349716187,neutral,0.014993634074926376
48,2018-12-16 07:00:00,It provides products and services for the development and commercialization of generic therapeutics.,0.037491463124752045,0.004338711500167847,0.9581698179244995,neutral,0.0331527516245842
49,2018-12-16 07:00:00,"It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment.",0.012711736373603344,0.007587260566651821,0.979701042175293,neutral,0.005124475806951523
50,2018-12-16 07:00:00,"Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.",0.012332897633314133,0.009420182555913925,0.9782468676567078,neutral,0.0029127150774002075
51,2018-12-16 07:00:00,Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates.,0.01376967690885067,0.00621530506759882,0.980014979839325,neutral,0.00755437184125185
52,2018-12-16 07:00:00,"It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research.",0.030752303078770638,0.004643227439373732,0.9646044969558716,neutral,0.02610907517373562
53,2018-12-16 07:00:00,It has API R&D and cGMP facilities in the United States and Europe.,0.05640144273638725,0.004473659675568342,0.9391248822212219,neutral,0.05192778259515762
54,2018-12-16 07:00:00,It supplies over 90 generic APIs.,0.0823248103260994,0.0054626138880848885,0.9122125506401062,neutral,0.07686219364404678
55,2018-12-16 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
56,2018-12-16 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
57,2018-12-16 07:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Peter Lynch has returned 335.77% vs. 159.89% for the S&P 500.",0.5258265733718872,0.4441112279891968,0.030062219128012657,positive,0.08171534538269043
58,2018-12-16 07:00:00,"For more details on this strategy, click here

About Peter Lynch : Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time.",0.8456207513809204,0.014854133129119873,0.13952510058879852,positive,0.8307666182518005
59,2018-12-16 07:00:00,Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street.,0.38180962204933167,0.017028477042913437,0.6011618971824646,neutral,0.36478114128112793
60,2018-12-16 07:00:00,"(""Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it,"" is one of his many pearls of wisdom.)",0.06574074923992157,0.02636720798909664,0.9078919887542725,neutral,0.03937353938817978
61,2018-12-16 07:00:00,"Lynch's bestseller One Up on Wall Street is something of a ""stocks for the everyman/everywoman"", breaking his approach down into easy-to-understand concepts.",0.17277808487415314,0.0457223504781723,0.7814995646476746,neutral,0.12705573439598083
62,2018-12-16 07:00:00,About Validea : Validea is an investment research service that follows the published strategies of investment legends.,0.01593991555273533,0.006665502674877644,0.9773945808410645,neutral,0.009274412877857685
63,2018-12-16 07:00:00,"Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.",0.08751808106899261,0.010206557810306549,0.9022753238677979,neutral,0.07731152325868607
64,2018-12-16 07:00:00,"For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.009221813641488552,0.018771808594465256,0.9720064401626587,neutral,-0.009549994952976704
